Carcinoma of Prostate and Breast Cancers are 2 major cancers from which men and women suffer in India and all over the world. Prostate carcinoma cell proliferation is dependent up to a late stage on testosterone and anti- androgens are employed as drugs to control the cancer. These are replaceable by a vaccine against LHRH. LHRH is a decapeptide hormone which stimulates Follicle stimulating hormone (FSH) and Luteinizing hormone (LH) production by the pituitary. These in turn act on the male/female gonads to not only generate sperm and egg, but also the respective sex hormones: estrogens in the females and testosterone in males. LHRH is identical in men and women and is a largely conserved decapeptide in all mammals. Thus a vaccine against LHRH is usable in both males and females to block eventually the production of testosterone or estrogens, as also in dogs and stray animals to block their fertility.

We made a synthetic vaccine against LHRH, replacing glycine at position 6 by lysine, to which via a linker, a carrier tetanus toxoid (TT) or diphtheria toxoid (DT) was conjugated [1] (Figure 1).

This vaccine generated bioeffective antibodies against LHRH, causing a virtual orchiectomy with testosterone declining to near zero levels [2] . After toxicology and safety studies and permission of Ethical and Drugs Regulatory Authorities, it was employed in 28 patients of Carcinoma of Prostate in 2 Centers of India, the All India Institute of Medical Sciences (AIIMS), New Delhi and Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, and one in Austria, the Urologische Zentrum Salzburg. Figure 2 shows its action in a patient in Austria. After 3 primary immunization of the vaccine given at monthly interval, anti-LHRH antibodies were generated, which brought down the testosterone of the patient, as also PSA (Prostate Specific Antigen). On decline of antibodies, these increased again, but were again brought down by a booster injection of the vaccine.

Figure 3 shows the effect of this vaccine in a patient at PGIMER, Chandigarh. On immunization, the prostatic mass shrunk perceptibly.

Table 1 gives the summary of observations in 12 patients investigated by Prof. SN Wadhwa at AIIMS, New Delhi. Six were given a dose of 200 μg of the vaccine and 6 immunized with 400 μg of the vaccine. 400 μg vaccine was more effective than 200 μg.

These studies indicate the utility of immunization against LHRH, which demand only periodic intervention and are cost effective as compared to the use of synthetic anti-androgens.

A stage arrives, when the cancer from which they suffer is no longer responsive to anti-androgens. This is the stage at which deaths occur of subjects suffering from this cancer. We developed monoclonal antibodies against

DU-145 and PC-3 cells apparently derived from patients dying of androgens-resistant cancers [3] . The monoclonals developed kill both DU-145 and PC-3 cells in dose dependent manner in the presence of complement (Figure 4).

The cytotoxic action of MoAb 730 plateaued at killing only 70% - 80% of DU-145 cells, pointing to the existence of heterogeneity of cell types in cancers, thereby demanding the requirement of additional antibodies targeting alternate epitopes. Three more monoclonal antibodies were developed [4] . Employing a combination of these enabled the killing of nearly 98% of DU 145 cells (Figure 5).

Thus the combination of antibodies did succeed in killing almost all cancer cells. The lysis of cancer cells by these antibodies in vitro demanded complement activation following the binding of the antibodies to the epitopes on membranes of DU-145 and PC-3 cells.

Human Chorionic Gonadotropin (hCG) is normally made by the early embryo soon after fertilization of the egg [5] . It plays an important role in implantation of the embryo and sustenance of pregnancy. Neither non pregnant females, nor healthy males make this hormone. Since late, however several reports have appeared on ectopic or unexpected expression of hCG or its subunits by a variety of cancers: lung cancer [6] , bladder carcinoma [7] [8] , pancreatic carcinoma [9] [10] , breast cancer [11] , cervical carcinoma [12] [13] , oral cancers [14] [15] , head and neck cancers [16] , prostate cancer [17] , renal carcinoma [18] , colon adenocarcinoma [19] , gastric carcinoma [20] [21] , vulva/vaginal cancers [22] [23] . Invariably the expression of hCG/subunits takes place at an advanced stage of cancer. The prognosis of such cancers is poor and survival adverse of the patients carrying the β-hCG expressing cancers [24] .

We developed a high affinity monoclonal antibody (PiPP) with high specificity for hCG [25] . This antibody has the capability of killing several hCG expressing cancers in culture. Figure 6 shows its concentration-de- pendent-cytotoxic action against a lung cancer cell line A549 [26] . It can also be used for imaging of metastatic cancer cells. Radio-iodinated antibodies home to cells to locate such cancers [27] .

We have developed also a highly immunogenic recombinant vaccine against hCG in which the β-subunit of hCG is linked to B subunit of heat labile enterotoxin of E. coli [28] . Figure 7 shows the vaccine design. The vaccine induces high titre bio-effective antibodies against hCG in BalbC mice [28] as well as in various other genetic strains of mice [29] . The vaccine should find a valuable application in treatment of cancer patients suffering from advanced stage cancers expressing ectopically hCG.

It is not inconceivable that anti-hCG antibodies alone, may fail to kill a cancer cell expressing hCG alone or in presence of complement. MOLT-4, T-lymphoblastic leukemia cells, are an example [30] . These are positive for hCG but PiPP fails to kill these cells in culture with or without complement.

An alternate strategy was adopted. We linked curcumin, a highly safe compound purified from curcumin longa. Curcumin has anti-inflammatory and anti-cancerous properties. By linking it to PiPP, it could reach the cancer cells expressing hCG by virtue of the ability of the antibody to recognize and bind with hCG expressed by these cells and thereafter deliver curcumin to these cells. The conjugate caused nearly 100% killing of cells [26] [31] . Almost all cancer cells were killed (Figure 8).

Thus antibody-curcumin conjugates can act as “Magic Bullets” reaching selectively the cancer cells expressing hCG and thereafter killing these via curcumin. Incidentally this approach will be highly economical. It can save the amount of antibody which needs to be given passively for therapeutic purposes.

The work recapitulated in this Review received research grants from the Indian Council of Medical Research, Department of Biotechnology, and Department of Science and Technology, Government of India.

G. P. Talwar,Jagdish C. Gupta,M. Diwan,J. Frick,S. K. Sharma,S. N. Wadhwa,R. M. Gupta,S. K. Gupta,Shilpi Purswani,Hemant K. Vyas, (2016) Vaccines and Antibodies for Therapeutic Use in Cancers. Journal of Cancer Therapy,07,370-377. doi: 10.4236/jct.2016.76040